Evaluating focal ablation treatments for prostate cancer
Official title: Prospective Single Institutional Study Evaluating the Outcomes for Patients Undergoing Ablative Therapies in the Management of Clinically Localized Prostate Cancer in the Primary and Salvage Setting
Run by University of Texas Southwestern Medical Center · NCT05478694 · Data updated 2026-11-12
This study is testing different types of heat and cold treatments for men with localized prostate cancer to see how well they work and how they affect quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | Men only |
| Enrollment | 225 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | February 1, 2023 |
| Main results expected | August 2026 |
| Study ends | August 2026 |
| Registry record updated | April 17, 2026 |
| Trial ID | NCT05478694 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men aged 18-90 with histologically confirmed localized prostate adenocarcinoma or local recurrence, who are eligible for standard ablative therapies.
✕Probably not a fit
Patients with non-organ confined disease, active urinary tract infections, or anatomical abnormalities preventing focal ablation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the efficacy and safety of various ablative therapies for localized prostate cancer, including cryoablation, brachytherapy, irreversible electroporation, high intensity focused ultrasound, and MRI-guided transurethral ultrasound ablation. The study will also evaluate quality of life outcomes and oncologic control following these treatments. Participants will receive standard of care ablative therapy in an outpatient setting, with treatments lasting between 2-4 hours. The study will focus on men diagnosed with prostate adenocarcinoma and local recurrence, ensuring a comprehensive understanding of treatment impacts.
Why it matters
Potential benefit: If successful, this study could provide insights into effective management strategies for localized prostate cancer, potentially improving patient outcomes and quality of life.
How similar studies have gone: Previous studies have shown promising results with various ablative therapies for prostate cancer, indicating that this approach is supported by existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy * Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease * Age 18-90 years. * Life expectancy \> 1 year * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Anatomic abnormalities that do not allow for focal ablation * Evidence of non-organ confined disease that is not feasible for ablation * Has active urinary traction infection
Where it's running
-
Utsw
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Daniel Segal, M.D. — University of Texas Southwestern Medical Center
- Study coordinator: Sonobia Garrett
- Email: Sonobia.Garrett@UTSouthwestern.edu
- Phone: 214/645-8482
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.